RaySearch Laboratories AB (CHIX:RAYBS) Other Current Receivables: kr348 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:RAYBS RaySearch Laboratories AB CHIX:RAYBS
95 GF Score
Price kr234.70
GF Value kr236.21
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Other Current Receivables?

RaySearch Laboratories AB CHIX:RAYBS 95 Other Current Receivables is kr348 Mil as of Jun. 2026. GuruFocus rates CHIX:RAYBS with a GF Score™ of 95/100 and a GF Value™ of kr236.21 (Fairly Valued). The stock has 2 warning signs investors should review.

RaySearch Laboratories AB's Other Current Receivables for the quarter that ended in Jun. 2026 was kr348 Mil.

RaySearch Laboratories AB's quarterly Other Current Receivables declined from Dec. 2025 (kr495.49 Mil) to Mar. 2026 (kr325.50 Mil) but then increased from Mar. 2026 (kr325.50 Mil) to Jun. 2026 (kr347.70 Mil).

RaySearch Laboratories AB's annual Other Current Receivables increased from Dec. 2023 (kr161.69 Mil) to Dec. 2024 (kr208.10 Mil) and increased from Dec. 2024 (kr208.10 Mil) to Dec. 2025 (kr495.49 Mil).

RaySearch Laboratories AB Other Current Receivables Related Terms

RaySearch Laboratories AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB Other Current Receivables Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.80 136.91 161.69 208.10 495.49

RaySearch Laboratories AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.88 353.90 495.49 325.50 347.70
CHIX:RAYBS
95GF Score
RaySearch Laboratories AB CHIX:RAYBS
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr348 Mil mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Other Current Receivables of kr348 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Other Current Receivables too high?
RaySearch Laboratories AB's current Other Current Receivables is kr348 Mil. Overall, RaySearch Laboratories AB has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Other Current Receivables compare to VEEV and BTSG?
RaySearch Laboratories AB's Other Current Receivables of kr348 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Healthcare Providers & Services company?
A good Other Current Receivables depends on the Healthcare Providers & Services industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Other Current Receivables is kr348 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Fairly Valued. The stock's GF Value™ is kr236.21, compared to a current price of kr234.70 — trading 0.6% below its estimated fair value. The current Other Current Receivables is kr348 Mil. RaySearch Laboratories AB's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Other Current Receivables is kr348 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued. The current stock price of kr234.70 is trading 0.6% below its estimated GF Value™ of kr236.21. GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.

Key valuation signals for CHIX:RAYBS:

  • Other Current Receivables: kr348 Mil
  • GF Value™: kr236.21 vs. price of kr234.70 (0.6% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
95GF Score

Get the complete analysis for CHIX:RAYBS

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr234.70
Price
kr236.21
GF Value